BRAF or MAP2K1 alterations were present in 80% of LCH patients, including BRAFV600E (10%), BRAFV600D (10%), BRAFN486_P490 (50%), and MAP2K1 (10%). Here, BRAF is linked to Langerhans cell histiocytosis.